AdAlta : Presentation Conference Schedule - January 2022

For personal use only

4 January 2022

ASX Announcement

ADALTA PRESENTING AT JANUARY BIOTECH CONFERENCES

MELBOURNE Australia, 4 January 2022: AdAlta Limited (ASX:1AD), the clinical stage drug discovery company developing novel therapeutic products from its i-body platform is participating virtually at Biotech Showcase™ 2022 Virtual conference during "J.P. Morgan Week 2022" and at H.C. Wainwright BioConnect. Highlights from its latest investor presentation (attached) will be presented by CEO and Managing Director, Dr Tim Oldham. Dr Oldham and COO, Dr Dallas Hartman, will be participating in partnering and networking programs at both events.

Biotech Showcase™ 2022 Virtual conference

Biotech Showcase, produced by Demy-Colton and EBD Group, will be held virtually on January 10-12, 2022 & January 17-19, 2022. Biotech Showcase is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year during what's known as JP Morgan Healthcare week - one of the industry's largest gatherings and busiest weeks.

Further details of the conference can be found at: https://informaconnect.com/biotech-

showcase/.

The pre-recorded video of Dr Oldham's presentation will be made available on AdAlta's

website.https://adalta.com.au/investors/presentations/

H.C. Wainwright Bioconnect Conference.

The H.C. Wainwright Bioconnect Conference will be held on January 10-13, 2022. Further details of the conference can be found at: https://hcwevents.com/bioconnect/.

Authorised for lodgement by:

Tim Oldham

CEO and Managing Director

January 2022

Notes to editor

About AdAlta

AdAlta Limited is a clinical stage drug development company headquartered in Melbourne, Australia. The Company is using its proprietary i-body technology platform to solve challenging drug targeting problems and generate a promising new class of single domain antibody protein therapeutics with the potential to treat some of today's most challenging medical conditions.

For personal use only

The i-body technology mimics the shape and stability of a unique and versatile antigen binding domain that was discovered initially in sharks and then developed as a human protein. The result is a range of unique proteins capable of interacting with high selectivity, specificity and affinity with previously difficult to access targets such as G-protein coupled receptors (GPCRs) that are implicated in many serious diseases. i-bodies are the first fully human single domain antibody scaffold and the first based on the shark motif to reach clinical trials.

AdAlta has completed Phase I clinical studies for its lead i-body candidate, AD-214, that is being developed for the treatment of Idiopathic Pulmonary Fibrosis (IPF) and other human fibrotic diseases for which current therapies are sub-optimal and there is a high unmet medical need.

The Company is also entering collaborative partnerships to advance the development of its i-body platform. It has an agreement with GE Healthcare to co-developi-bodies as diagnostic imaging agents against Granzyme B, a biomarker of response to immunooncology drugs, a program now in preclinical development. It also has a collaboration with Carina Biotech to co-develop precision engineered, i-body enabled CAR-T cell therapies to bring new hope to patients with cancer.

AdAlta's strategy is to maximise the products developed using its next generation i-body platform by internally discovering and developing selected i-body enabled product candidates against GPCRs implicated in fibrosis, inflammation and cancer and partnering with other biopharmaceutical companies to develop product candidates against other classes of receptor, in other indications, and in other product formats.

Further information can be found at: https://adalta.com.au

About Biotech Showcase

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 14th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

Further information can be found at:https://informaconnect.com/biotech-showcase/

About H.C. Wainwright & Co.

H.C. Wainwright & Co. is one of America's oldest and most trusted financial institutions. H.C. Wainwright blends traditional values with innovative services, operating with integrity and offering leading-edge investment banking, corporate finance, and strategic advisory services to public and private growth companies across multiple sectors and regions. H.C. Wainwright Bioconnect Conference offers presenting companies, fireside discussions, meetings with H.C. Wainwright investment banking & research teams, and evenings of virtual entertainment.

Further information can be found at: https://hcwevents.com/bioconnect/

For personal use only

For more information, please contact:
Investors	Media
Tim Oldham, CEO & Managing Director	IR Department
Tel: [phone]	Tel: [phone]
E:[e-mail]	E:[e-mail]

onal use only

Corporate overview

December 2021

	INVESTOR PRESENTATION - DECEMBER 2021	3

AdAlta today

AdAlta is building significant growth momentum while retaining agility to respond and adapt to data and opportunities

onlyuse

onal1.

2.

3.

• i-bodyplatform: can create therapeutics addressing targets underserved by traditional antibodies
• Fibrosis/inflammation: lead asset AD-214preparing for Phase II clinical trial
• • US$3b Idiopathic Pulmonary Fibrosis (IPF) market today,1 multiple US$b indication potential
• Second target in discovery
• Immuno-oncology:two co-development collaborations
• • GZMB PET imaging agent with GE Healthcare: US$6.4b PET imaging agent market2
  • i-bodyenabled CAR-T with Carina Biotech: US$20b market by 20283
• Continuing to build out pipeline with additional internal and external programs: targeting 10 by 2023

GlobalData, Idiopathic Pulmonary Fibrosis Opportunity Analysis and Forecasts to 2029, November 2020

2027 forecast by Global Industry Analysts, Imaging Agents: Global Market Trajectory and Analytics, April 2021 2028 forecast by Grandview Research, "T-cellTherapy Market Size, Share & Trends Analysis" Feb 2021